Omeros Corporation $OMER Stake Lifted by Profund Advisors LLC

Profund Advisors LLC raised its holdings in shares of Omeros Corporation (NASDAQ:OMER) by 206.3% in the third quarter, Holdings Channel.com reports. The firm owned 80,616 shares of the biopharmaceutical company’s stock after buying an additional 54,297 shares during the period. Profund Advisors LLC’s holdings in Omeros were worth $1,535,000 as of its most recent SEC filing.

A number of other hedge funds have also recently bought and sold shares of the business. BlackRock Inc. acquired a new position in shares of Omeros in the 2nd quarter valued at approximately $57,484,000. State Street Corp boosted its stake in shares of Omeros by 20.9% during the 2nd quarter. State Street Corp now owns 2,319,906 shares of the biopharmaceutical company’s stock valued at $22,062,000 after buying an additional 400,331 shares during the last quarter. Corient Private Wealth LP acquired a new stake in shares of Omeros during the second quarter worth approximately $6,274,000. Bank of America Corp DE grew its position in shares of Omeros by 57.8% during the first quarter. Bank of America Corp DE now owns 204,805 shares of the biopharmaceutical company’s stock worth $2,163,000 after buying an additional 74,997 shares in the last quarter. Finally, Wellington Management Group LLP grew its position in shares of Omeros by 9.2% during the second quarter. Wellington Management Group LLP now owns 204,541 shares of the biopharmaceutical company’s stock worth $1,945,000 after buying an additional 17,241 shares in the last quarter. Institutional investors and hedge funds own 48.79% of the company’s stock.

Omeros Stock Down 3.3%

Shares of NASDAQ OMER opened at $17.83 on Tuesday. The stock’s 50 day moving average price is $18.49 and its two-hundred day moving average price is $13.49. Omeros Corporation has a 52-week low of $6.24 and a 52-week high of $21.24. The stock has a market capitalization of $1.29 billion, a P/E ratio of 13.93 and a beta of 2.57.

Omeros (NASDAQ:OMER) last issued its earnings results on Wednesday, August 12th. The biopharmaceutical company reported $0.02 EPS for the quarter, topping the consensus estimate of ($0.27) by $0.29. The firm had revenue of $28.53 million during the quarter, compared to analyst estimates of $12.69 million. On average, analysts anticipate that Omeros Corporation will post -0.37 EPS for the current year.

Insider Buying and Selling at Omeros

In other news, CAO David Borges sold 10,000 shares of the firm’s stock in a transaction dated Wednesday, September 23rd. The shares were sold at an average price of $20.95, for a total value of $209,500.00. Following the transaction, the chief accounting officer directly owned 5,000 shares in the company, valued at approximately $104,750. This trade represents a 66.67% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Arnold Hanish sold 10,000 shares of the firm’s stock in a transaction dated Thursday, August 27th. The stock was sold at an average price of $18.95, for a total transaction of $189,500.00. Following the completion of the transaction, the director owned 5,000 shares in the company, valued at approximately $94,750. The trade was a 66.67% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 105,906 shares of company stock valued at $1,989,705 over the last three months. 10.50% of the stock is currently owned by company insiders.

Wall Street Analyst Weigh In

A number of brokerages recently issued reports on OMER. Wall Street Zen upgraded shares of Omeros from a “hold” rating to a “buy” rating in a research note on Saturday, August 15th. Cantor Fitzgerald reiterated an “overweight” rating and set a $22.00 price objective on shares of Omeros in a research note on Wednesday, October 14th. HC Wainwright reissued a “buy” rating on shares of Omeros in a report on Monday, July 27th. Weiss Ratings raised shares of Omeros from a “hold (c-)” rating to a “hold (c)” rating in a report on Thursday, October 8th. Finally, Zacks Research downgraded shares of Omeros from a “strong-buy” rating to a “hold” rating in a research report on Monday, July 13th. Three investment analysts have rated the stock with a Buy rating and two have issued a Hold rating to the stock. According to data from MarketBeat, Omeros has an average rating of “Moderate Buy” and a consensus price target of $30.33.

About Omeros

Omeros Corporation (NASDAQ: OMER) is a biopharmaceutical company focused on discovering, developing and commercializing therapies for disorders involving the complement, immune and coagulation systems. The company has also developed a pipeline of investigational therapies aimed at treating serious diseases involving complement activation and immune-system dysfunction. The company is headquartered in Seattle, Washington, and was founded in 1994.

Its leading investigational programs have included narsoplimab, which targets the lectin pathway of the complement system, and OMS906, an antibody designed to inhibit MASP-3 and regulate the alternative pathway.